Don't want to miss the best from Business Standard?
Wednesday, December 03, 2025 | 03:21 AM ISTहिंदी में पढें
Near-term upsides from deal with AbbVie may be priced in Glenmark's stock
Glenmark's $700 million deal with AbbVie for ISB-2001 could unlock significant upside, though analysts note the potential is already priced in, with stock surging post-announcement
 "Glenmark Pharma, AbbVie, ISB-2001, licensing deal, oncology, multiple myeloma, cancer, royalties, EBITDA growth, milestone payments")
premium
Glenmark has also reduced its financial leverage and strengthened its abbreviated new drug application (ANDA) pipeline for the US market and reorganised its domestic business
Glenmark Pharma (GNP) has just signed an exclusive licensing deal with AbbVie through its subsidiary, Ichnos Glenmark Innovation (IGI), for its lead investigational asset, ISB-2001.
The deal could be transformative as it leverages IGI’s BEAT protein platform for oncology and auto-immune diseases.
It also has the potential of ISB-2001 to treat relapsed and refractory multiple myelomas and underlines the commercial viability of ISB-2001 following successful clinical trials.
AbbVie is considered a diversified biopharma leader.
In oncology, it has built a robust presence anchored by cornerstone therapies. This has improved the treatment for chronic lymphocytic leukaemia and other B-cell malignancies, generating
